Whole Exome Analysis of NIAAA Clinical Center pATIENTS 75N98026Q00677
Summary
AI-generated · Jun 23, 2026Provide whole-exome sequencing for the NIAAA Clinical Center patient cohort to identify sequence-variant differences and changes in response to treatment over many years, supporting efforts to uncover underlying causes of alcohol-related disorders.
To preserve analytical integrity and enable consistent comparisons across samples collected at different times, all samples must be processed on a single enrichment and sequencing platform—the AmpliSeq Exome enrichment system and ION sequencing platform—since different platforms have distinct error patterns; this approach has previously been applied to over 2,000 patients.
The NIAAA Clinical Center patient cohort has been analyzed patients for sequence variant differences, and changes in response to treatment over the course of many years as part of an effort to identify underlying causes of alcohol related disorders. Analysis has previously been performed on over 2000 patients using the AmpliSeq Exome enrichment system and sequenced on the ION sequencing platform because it provides the capability of cost-effective high throughput whole-exome genome-wide analysis. The use of a single enrichment and sequencing platform with consistent information content is essential for analysis of samples screened at different times and it is therefore imperative for analytical integrity that all samples in the study are processed on the same sequencing platform, as each platform has a unique pattern of error
From Presolicitation posted on Jun 22, 2026Notice history
1-
Presolicitation LATEST Posted Jun 22, 2026
Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA